Precision BioSciences, Inc. (DTIL): Price and Financial Metrics
GET POWR RATINGS... FREE!
DTIL POWR Grades
- Sentiment is the dimension where DTIL ranks best; there it ranks ahead of 80.27% of US stocks.
- The strongest trend for DTIL is in Value, which has been heading down over the past 177 days.
- DTIL ranks lowest in Momentum; there it ranks in the 3rd percentile.
DTIL Stock Summary
- Revenue growth over the past 12 months for PRECISION BIOSCIENCES INC comes in at -62.99%, a number that bests only 2.63% of the US stocks we're tracking.
- The volatility of PRECISION BIOSCIENCES INC's share price is greater than that of 96.61% US stocks with at least 200 days of trading history.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for DTIL comes in at -85.4% -- higher than that of only 6.69% of stocks in our set.
- Stocks that are quantitatively similar to DTIL, based on their financial statements, market capitalization, and price volatility, are MRUS, VXRT, FDMT, MRKR, and AGIO.
- DTIL's SEC filings can be seen here. And to visit PRECISION BIOSCIENCES INC's official web site, go to www.precisionbiosciences.com.
DTIL Valuation Summary
- In comparison to the median Healthcare stock, DTIL's price/earnings ratio is 107.65% lower, now standing at -1.5.
- DTIL's price/sales ratio has moved down 75 over the prior 42 months.
Below are key valuation metrics over time for DTIL.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DTIL | 2022-09-23 | 3.6 | 1.3 | -1.5 | 0.2 |
| DTIL | 2022-09-22 | 3.8 | 1.4 | -1.5 | 0.2 |
| DTIL | 2022-09-21 | 4.0 | 1.5 | -1.6 | 0.1 |
| DTIL | 2022-09-20 | 4.1 | 1.5 | -1.7 | 0.0 |
| DTIL | 2022-09-19 | 4.4 | 1.6 | -1.8 | -0.1 |
| DTIL | 2022-09-16 | 4.5 | 1.6 | -1.8 | -0.1 |
DTIL's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DTIL has a Quality Grade of C, ranking ahead of 57.32% of graded US stocks.
- DTIL's asset turnover comes in at 0.5 -- ranking 82nd of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows DTIL's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.500 | 1 | -1.846 |
| 2021-03-31 | 0.176 | 1 | -3.839 |
| 2020-12-31 | 0.135 | 1 | -3.174 |
| 2020-09-30 | 0.109 | 1 | -3.116 |
| 2020-06-30 | 0.087 | 1 | -3.034 |
| 2020-03-31 | 0.097 | 1 | -2.717 |
DTIL Price Target
For more insight on analysts targets of DTIL, see our DTIL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $19.13 | Average Broker Recommendation | 1.45 (Moderate Buy) |
DTIL Stock Price Chart Interactive Chart >
DTIL Price/Volume Stats
| Current price | $1.30 | 52-week high | $11.73 |
| Prev. close | $1.31 | 52-week low | $1.11 |
| Day low | $1.30 | Volume | 403,600 |
| Day high | $1.41 | Avg. volume | 1,612,725 |
| 50-day MA | $1.59 | Dividend yield | N/A |
| 200-day MA | $3.00 | Market Cap | 144.06M |
Precision BioSciences, Inc. (DTIL) Company Bio
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.
Latest DTIL News From Around the Web
Below are the latest news stories about PRECISION BIOSCIENCES INC that investors may wish to consider to help them evaluate DTIL as an investment opportunity.
Trade Alert: The Chief Financial Officer Of Precision BioSciences, Inc. (NASDAQ:DTIL), John Kelly, Has Just Spent US$60k Buying 38% More SharesWhilst it may not be a huge deal, we thought it was good to see that the Precision BioSciences, Inc. ( NASDAQ:DTIL... |
Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine SummitDURHAM, N.C., September 22, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Jefferies Cell & Genetic Medicine Summit taking place September 29-30, 2022. |
Precision BioSciences to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment ConferenceDURHAM, N.C., September 07, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022. |
Precision BioSciences Announces Senior Leadership Organizational ChangesDURHAM, N.C., September 02, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced promotions and organizational changes that impact responsibilities within the company’s senior leadership team reporting to Michael Amoroso, Chief Executive Officer (CEO). |
Analysts Offer Insights on Healthcare Companies: Albireo Pharma (ALBO), Precision BioSciences (DTIL) and Ayala Pharmaceuticals (AYLA)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Albireo Pharma (ALBO – Research Report), Precision BioSciences (DTIL – Research Report) and Ayala Pharmaceuticals (AYLA – Research Report) with bullish sentiments. Albireo Pharma (ALBO) In a report released today, Andreas Argyrides from Wedbush maintained a Buy rating on Albireo Pharma, with a price target of $61.00. The company's shares closed last Monday at $24.93. According to TipRanks.com, Argyrides is a 3-star analyst with an average return of -6.7% and a 42.9% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Arrowhead Pharmaceuticals, and Milestone Pharmaceuticals. |
DTIL Price Returns
| 1-mo | -17.72% |
| 3-mo | -15.03% |
| 6-mo | -61.08% |
| 1-year | -88.85% |
| 3-year | -82.71% |
| 5-year | N/A |
| YTD | -82.43% |
| 2021 | -11.27% |
| 2020 | -39.96% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...